Treatment of multiple sclerosis

Acta Clinica Croatica

Volumn 48, Issue 3, 2009, Pages 349-353

  Bošnjak Pašic, Marija ^a,b   Vidrih, Branka ^b   Miškov, Snježana ^a   Demarin, Vida ^a  

^a KBC Zagreb   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Immunosuppressive agents therapeutic use; Interferon, beta therapeutic use; Multiple sclerosis therapy

Indexed keywords

ACETAZOLAMIDE; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EXTAVIA; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; NOVARTONE; PLACEBO; SALUMEDROL; UNCLASSIFIED DRUG;

ACNE; ALLERGY; ANAPHYLACTIC SHOCK; ANEMIA; ASEPTIC MENINGITIS; BACKACHE; CATARACT; CYTOPENIA; DEPRESSION; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DUODENUM ULCER; ECZEMA; FLU LIKE SYNDROME; FLUSHING; GLUCOSE BLOOD LEVEL; HEADACHE; HIRSUTISM; HUMAN; HYPERTENSION; KIDNEY TUBULE DAMAGE; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NEUTROPENIA; OSTEOPOROSIS; PLASMA VISCOSITY; PLASMAPHERESIS; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; SHIVERING; SIDE EFFECT; SKIN DEFECT; TREATMENT RESPONSE; URTICARIA;

HUMANS; MULTIPLE SCLEROSIS;

EID: 74049107200     PISSN: 03539466     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Chofflon M. Mechanisms of action for treatments in multiple sclerosis. Biodrugs 2005;19:299-308
2. Isaacs A, Lindemann J. Virus interference. The interferon. Proc R Soc Lond (Biol) 1957;147:258-67
3. Iz rada struène grupe za lijekove Ministarstva zdravstva Republike Hrvatske. Pharmaca 1997;35:49-60
4. The IFNB MS Study Group. Interferon beta-lb is effective in RRMS : clinical results of a multicentre, randomized, doubleblind, plecebo-controlled trial. Neurology 1993;43:665-61
5. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D'Amico R. Interferons in relapsing rmitting multiple sclerosis: a systematic review. Lancet 2003;361:545-52
6. Sharief MK. Dose and frequency of administration of interferon-beta affect its efficacy in multiple sclerosis. Clin drug Investig 2003;23:551-9
7. The PRISMS Study Group (Prevention of Relapses and Disability by Interferon Beta-la Subcutaneously in Multiple Sclerosis). Randomised double-blind placebo controlled study of interferon beta-la in relapsing/remitting multiple sclerosis. Lancet 1988;352:1498-504
8. Jacobs LD, Cookfair DL, Rudick RA. Results of a phase III trialof intramuscular recombinant beta interferon as treatment of multiple sclerosis. Ann Neurol 1994;36:256
9. Jacobs LD, Cookfair DL, Rudick RA. Intramuscular interferon-beta la for a disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:258-94
10. IFNB MS Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I MRI analysis results of a multicentre, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
11. Kappos L. New aspects in the treatment of multiple sclerosis with interferon beta 1b. J Neurol 2004;251 (Suppl 4):IV/1;DOI 10.1007/00415-004-1401- 4
12. Durelli L. Is multiple sclerosis a disease that requires frequent beta interferon dosing? J Neurol 2004;251 (Suppl 4) : IV/13-IV/24;DOI 10.1007/00415-004-1404-1
13. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357:1576-82
14. Galetta SL. The Controlled High Risk Avonex Multiple Sclerosis Trial (CHAMPS study). J Neuroophthalmol 2001;21:292-5
15. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH et al. Treatment with interferon beta-1b delays conversion t clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9
16. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis:a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-97
17. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Extended use of glatiramer acetat (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701-8
18. Tyndall A, Saccardi R. Haematopoetic stem cell transplantation in the treatment of severe autoimune disease;results from phase I/II studies, prospective randomized trials and future direction. Br Soc Immunol Clin Exp Immunol 2005;141:1-9
19. Mancardi GL. Autologus haematopoetic stem cell transplantation. neurol sci 2005;26:S19.
20. Hohlfeld R, Wekerle H. Drug insight : using monocvlonal antibodies to treat multiple sclerosis. Nature Clin Pract Neurol 2005;1:34-44
21. O'Leary S, Beavin J, Bishop C, Capolino L, Greinel e, Hudson E. Practical guidelines for administering natalizumab:a nursing perspective. Int MS Care 2007;9:1-8
22. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-35
23. Tysabri® (natalizumab) (package insert). Cambridge, MA: Biogen Idec, Inc. 2006
24. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63-6
25. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
26. Post-hos analysis of the AFFIRM study. Cambridge, MA: Biogen Idec, Inc. 2005
27. Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 2005;5:721-7